Verlinsky Y, Kuliev A
Reproductive Genetics Institute, Illinois Masonic Medical Center, Chicago 60657.
Baillieres Clin Obstet Gynaecol. 1994 Mar;8(1):177-96. doi: 10.1016/s0950-3552(05)80031-8.
One of the limitations of existing assisted reproduction practices is that couples at genetic risk to their offspring have to face the abortion of an affected fetus following prenatal diagnosis. This is not acceptable as a measure to avoid a congenital disease in many communities or ethnic groups, where there is a great need for a method to diagnose and avoid the affected embryo before implantation and establishment of the pregnancy. In fact, preimplantation diagnosis is needed also for those who accept prenatal diagnosis as an option to avoid the birth of an affected child, because in most of the cases the couples are at high (25-50%) risk of having a child with a recessive or dominant disease, leading to their unfortunate experience of undergoing two or more abortions of wanted pregnancies. Two methods for preimplantation genetic diagnosis (PGD) have been recently developed and implemented in the framework of IVF. PGD can be performed by micromanipulation and biopsy of the first polar body before fertilization, or by blastomere biopsy before implantation of the pre-embryo. Another potentially realistic approach is blastocyst biopsy, which is still under development and has not yet been tested in clinical practice. Available data suggest that preimplantation diagnosis is safe, as no detrimental effects have been observed in studies on the viability of biopsied pre-embryos. Genetic analysis of biopsied gametes and blastomeres is now possible by DNA analysis, while enzyme analysis and preimplantation diagnosis of chromosomal disorders are still at the research stage. The accuracy of DNA analysis in preimplantation diagnosis is clear from available data on the outcome of preimplantation diagnosis: eight children free of genetic disease have been born following preimplantation diagnosis of cystic fibrosis, haemophilia A and other X-linked conditions. However, two misdiagnoses have been also described, showing the need for further development and improvement in the accuracy, efficiency and efficacy of DNA analysis in single cells. A particularly important implication for assisted reproduction practices can be expected from the further development and improvement of methods for preimplantation cytogenetic analysis. Although the efficiency and efficacy of these methods are not yet acceptable for application in clinical practice, considerable progress has been made, providing clear evidence for their feasibility in the near future. In spite of the high cost of the preimplantation diagnostic technique at present, its development is highly justified for high risk families as it provides a wider range of options for avoiding the risk of having an affected child.(ABSTRACT TRUNCATED AT 400 WORDS)
现有辅助生殖技术的局限性之一在于,有遗传风险的夫妇在产前诊断后不得不面对受影响胎儿的流产。在许多社区或族群中,这作为一种避免先天性疾病的措施是不可接受的,因为这些地方非常需要一种在胚胎植入和妊娠确立之前诊断并避免受影响胚胎的方法。事实上,对于那些接受产前诊断作为避免患病儿童出生选择的夫妇来说,也需要进行植入前诊断,因为在大多数情况下,夫妇生育隐性或显性疾病患儿的风险很高(25%-50%),这导致他们不幸地经历两次或更多次想要的妊娠流产。最近在体外受精的框架内开发并实施了两种植入前基因诊断(PGD)方法。PGD可以通过受精前对第一极体进行显微操作和活检来进行,或者通过植入前胚胎的卵裂球活检来进行。另一种潜在可行的方法是囊胚活检,该方法仍在开发中,尚未在临床实践中进行测试。现有数据表明植入前诊断是安全的,因为在对活检后胚胎的活力研究中未观察到有害影响。通过DNA分析现在可以对活检的配子和卵裂球进行基因分析,而酶分析和染色体疾病的植入前诊断仍处于研究阶段。从植入前诊断的结果现有数据可以清楚地看出DNA分析在植入前诊断中的准确性:在对囊性纤维化、甲型血友病和其他X连锁疾病进行植入前诊断后,已经有8名无遗传疾病的儿童出生。然而,也有两例误诊的报道,这表明需要进一步开发和提高单细胞DNA分析的准确性、效率和效能。植入前细胞遗传学分析方法的进一步开发和改进有望对辅助生殖技术产生特别重要的影响。尽管这些方法的效率和效能目前在临床实践中还不能接受,但已经取得了相当大的进展,为它们在不久的将来的可行性提供了明确的证据。尽管目前植入前诊断技术成本高昂,但对于高危家庭来说,其发展是非常合理的,因为它为避免生育患病儿童的风险提供了更广泛的选择。(摘要截选至400字)